These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 18793589

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes.
    He YL, Sabo R, Picard F, Wang Y, Herron J, Ligueros-Saylan M, Dole WP.
    Curr Med Res Opin; 2009 May; 25(5):1265-72. PubMed ID: 19364302
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes.
    He YL, Ito H, Yamaguchi M, Terao S, Shimada S, Irie S, Sekiguchi K.
    Int J Clin Pharmacol Ther; 2012 Apr; 50(4):237-47. PubMed ID: 22456294
    [Abstract] [Full Text] [Related]

  • 6. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    He YL, Sabo R, Riviere GJ, Sunkara G, Leon S, Ligueros-Saylan M, Rosenberg M, Dole WP, Howard D.
    Curr Med Res Opin; 2007 May; 23(5):1131-8. PubMed ID: 17519080
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
    Sunkara G, Sabo R, Wang Y, He YL, Campestrini J, Rosenberg M, Howard D, Dole WP.
    J Clin Pharmacol; 2007 Sep; 47(9):1152-8. PubMed ID: 17656620
    [Abstract] [Full Text] [Related]

  • 12. Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects.
    Patel CG, Kornhauser D, Vachharajani N, Komoroski B, Brenner E, Handschuh del Corral M, Li L, Boulton DW.
    Diabetes Obes Metab; 2011 Jul; 13(7):604-14. PubMed ID: 21332626
    [Abstract] [Full Text] [Related]

  • 13. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
    Mikhail N.
    Vasc Health Risk Manag; 2008 Jul; 4(6):1221-7. PubMed ID: 19337535
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
    Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S.
    Diabetes Obes Metab; 2007 Mar; 9(2):166-74. PubMed ID: 17300592
    [Abstract] [Full Text] [Related]

  • 17. A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes.
    Vianna AGD, Lacerda CS, Pechmann LM, Polesel MG, Marino EC, Faria-Neto JR.
    Diabetes Res Clin Pract; 2018 May; 139():357-365. PubMed ID: 29596951
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.